Deliver Your News to the World

Affibody AB appoints Dr. Ulf Boberg as Chief Executive


WEBWIRE

June 1, 2006

STOCKHOLM, Sweden, - Affibody AB today announces that Dr. Ulf Boberg has been appointed Chief Executive Officer as from June 1, 2006.

Dr. Ulf Boberg, who joined Affibody in January 2006 as Senior Vice President Development, replaces Dr. Carl-Johan Dalsgaard who has been acting Chief Executive Officer of Affibody since December 2005. Dr. Dalsgaard is a partner of Affibody’s largest shareholder HealthCap and will remain a non-executive board member of Affibody.

Dr. Boberg holds a PhD in medical science, an MBA from Uppsala University and has 18 years experience from the pharmaceutical and biotechnology industry. Most recently, Dr. Boberg was CEO of Global Genomics AB. Before that, he held the senior roles of vice president and head of the Development Division at Astra Pain Control, leading a team of 170 people, and vice president and R&D site general manager at AstraZeneca. In 2000, Dr. Boberg left AstraZeneca to become investment manager at LinkMed AB. Earlier in his career, he held positions including Head of Medical Research at Gambro, CEO of PMC Clinical Research AB and CEO of Alfta Rehab Center.

Karl Swartling, Affibody’s Chairman, said, “I am very pleased to announce Ulf’s appointment today. His work to date for the company has been very impressive and we greatly value his commercial experience as Affibody’s product pipeline for molecular imaging in oncology approaches the market.”

Dr. Ulf Boberg, CEO, said, “What attracted me to Affibody was the potential of its product pipeline in oncology for both molecular imaging and targeted therapy using its unique Affibody® molecules. The company has been increasing its focus over the past few years in optimizing this technology and looks now to be poised to begin capitalizing on its hard work. It is an exciting time to be involved with Affibody and I look forward to the future challenges we will face in bringing our products to market in the near term.”

For further information, please contact:
Affibody AB
Karl Swartling, Chairman of the board
+46 8 614 18 26
Ulf Boberg, Chief Executive Officer
+46 8 598 838 15
ulf.boberg@affibody.com

Citigate Dewe Rogerson
David Dible, Mark Swallow, Yvonne Alexander
+44 (0)207 638 9571



WebWireID14756





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.